Differential regulation of IL-17A and IL-17F via STAT5 contributes to psoriatic disease
Journal of Allergy and Clinical Immunology · 2023-09 · 152 (3) · 783-798
DOI: 10.1016/j.jaci.2023.03.035 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Allergy and Clinical Immunology, 2023-09. Verfasst von Suzanne Cole und 14 weiteren Autor:innen. Beteiligte Einrichtung: UCB Pharma, Slough. Electronic address: Suzanne.cole@outlook.com. Hauptthemen laut MEDLINE: Interleukin-17, STAT5 Transcription Factor. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 56 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: IL-17A plays a pivotal pathogenic role in several immune-mediated inflammatory diseases. Despite sharing 50% sequence homology with IL-17A, the role of IL-17F remains less clear. Clinical findings suggest that dual inhibition of IL-17A and IL-17F in psoriatic disease is more efficacious than IL-17A inhibition alone, positing a pathogenic role for IL-17F. OBJECTIVE: We characterized the regulation of IL-17A and IL-17F in psoriatic disease. METHODS: Using both in vitro systems and lesional skin tissue from patients, we interrogated the chromosomal, transcriptional, and protein expression landscape of IL-17A+ and IL-17F+ TH17 cells. Alongside established assays such as single-cell RNA sequencing, we developed a novel cytokine-capture technique that was combined with chromatin immunoprecipitation sequencing and RNA sequencing. RESULTS: We confirm a preferential elevation of IL-17F over IL-17A in psoriatic disease and show that expression of each isoform predominantly occurs in distinct cell populations. The expression of both IL-17A and IL-17F exhibited a high degree of plasticity, with the balance between the 2 isoforms influenced by proinflammatory signaling and by anti-inflammatory drugs such as methylprednisolone. This plasticity was reflected in a broad H3K4me3 region at the IL17A-F locus, while opposing effects of STAT5/IL-2 signaling were observed for each of the 2 genes. Functionally, higher IL17F expression was linked to greater cell proliferation. CONCLUSION: There are key differences in the regulation of IL-17A and IL-17F in psoriatic disease, leading to distinct inflammatory cell populations. As such, we propose that both IL-17A and IL-17F neutralization may be required to maximally inhibit IL-17-driven pathology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- UCB Pharma, Slough. Electronic address: Suzanne.cole@outlook.com.
- UCB Pharma, Slough.
- Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Oxford.
- Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow.
- Monasterium Laboratory Skin and Hair Research Solutions, Munster.
- UCB Pharma, Slough. Electronic address: ashmaroof@gmail.com.
Zitieren
APA
Cole, S., Manghera, A., Burns, L., Barrett, J., Yager, N., Rhys, H., Skelton, A., Cole, J., Goodyear, C. S., Griffiths, M., Baeten, D., Bertolini, M., Shaw, S., Al-Mossawi, H., & Maroof, A. (2023). Differential regulation of IL-17A and IL-17F via STAT5 contributes to psoriatic disease. Journal of Allergy and Clinical Immunology, 152(3), 783-798. https://doi.org/10.1016/j.jaci.2023.03.035
Vancouver
Cole S, Manghera A, Burns L, Barrett J, Yager N, Rhys H, et al. Differential regulation of IL-17A and IL-17F via STAT5 contributes to psoriatic disease. Journal of Allergy and Clinical Immunology. 2023;152(3):783-798. doi:10.1016/j.jaci.2023.03.035
BibTeX
@article{Cole2023,
author = {Cole, Suzanne and Manghera, Avneet and Burns, Lachrissa and Barrett, Janine and Yager, Nicole and Rhys, Hefin and Skelton, Andrew and Cole, John and Goodyear, Carl S and Griffiths, Meryn and Baeten, Dominique and Bertolini, Marta and Shaw, Stevan and Al-Mossawi, Hussein and Maroof, Asher},
title = {Differential regulation of IL-17A and IL-17F via STAT5 contributes to psoriatic disease},
journal = {Journal of Allergy and Clinical Immunology},
year = {2023},
volume = {152},
number = {3},
pages = {783--798},
doi = {10.1016/j.jaci.2023.03.035}
}
EUVIMED